Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
137 studies found for:    "Acute promyelocytic leukemia"
Show Display Options
Rank Status Study
1 Completed Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA)
Condition: Acute Promyelocytic Leukemia
Intervention: Drug: AIDA
2 Completed Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005)
Condition: Acute Promyelocytic Leukemia
Interventions: Drug: ATRA;   Drug: Idarubicina;   Drug: Mitoxantrone;   Drug: ARA-C
3 Recruiting Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)
Condition: Acute Promyelocytic Leukemia
Interventions: Drug: Realgar-Indigo naturalis formula;   Drug: all-trans retinoic acid;   Drug: Arsenic trioxide;   Drug: Hydroxyurea
4 Unknown  Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia
Condition: Acute Promyelocytic Leukemia
Intervention: Drug: Single agent arsenic trioxide
5 Recruiting Proteasome Inhibition in Acute Promyelocytic Leukemia
Condition: Relapsed Acute Promyelocytic Leukemia
Intervention: Drug: Bortezomib
6 Unknown  Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia
Condition: Acute Promyelocytic Leukemia
Intervention: Drug: NRX 195183 Soft Gelatin Capsule
7 Recruiting Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia
Condition: Acute Promyelocytic Leukemia
Interventions: Drug: Arsenic trioxide;   Drug: Idarubicin;   Drug: Cytarabine;   Drug: Tretinoin;   Drug: Mitoxantrone;   Drug: Mercaptopurine;   Drug: Methotrexate
8 Unknown  Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic
Conditions: Relapsed Acute Promyelocytic Leukemia;   Refractory Acute Promyelocytic Leukemia
Interventions: Drug: Arsenic trioxide;   Drug: Trisenox
9 Terminated Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia
Condition: Acute Promyelocytic Leukemia
Interventions: Drug: Tamibarotene;   Drug: Arsenic trioxide
10 Recruiting French Registry of First-line Treatment of Acute Promyelocytic Leukemia
Condition: Acute Promyelocytic Leukemia
Intervention:
11 Completed Long-Term Quality of Life in Patients With Acute Promyelocytic Leukemia
Condition: Acute Promyelocytic Leukemia
Intervention: Other: Health Related Quality of Life (HRQOL) measures
12 Withdrawn New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia
Condition: Acute Promyelocytic Leukemia
Interventions: Drug: NRX 195183 (retinoid analogue);   Drug: Arsenic Trioxide
13 Active, not recruiting Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
Condition: Acute Promyelocytic Leukemia
Intervention: Drug: Tretinoin and Arsenic Trioxide
14 Completed Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)
Condition: Acute Promyelocytic Leukemia
Interventions: Drug: Arsenic Trioxide;   Procedure: Autologous Transplantation;   Procedure: Allogenic Transplantation;   Drug: ATRA
15 Unknown  AIDA 2000 Guidelines
Condition: Acute Promyelocytic Leukemia
Intervention: Drug: all-trans retinoic acid (ATRA)
16 Recruiting Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL
Condition: Acute Promyelocytic Leukemia
Interventions: Drug: ATRA+arsenic;   Drug: ATRA+chemo
17 Completed All-trans Retinoic Acid, and Arsenic +/- Gemtuzumab
Condition: Acute Promyelocytic Leukemia
Interventions: Drug: All-Trans Retinoic Acid (ATRA);   Drug: Arsenic Trioxide (ATO);   Drug: Idarubicin
18 Active, not recruiting Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Conditions: Childhood Acute Promyelocytic Leukemia (M3);   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions: Drug: arsenic trioxide;   Drug: mitoxantrone hydrochloride;   Other: diagnostic laboratory biomarker analysis;   Drug: idarubicin;   Drug: tretinoin;   Drug: cytarabine;   Drug: mercaptopurine tablet;   Drug: methotrexate
19 Completed Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL
Condition: Acute Promyelocytic Leukemia
Intervention: Drug: Tamibarotene
20 Recruiting Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia
Conditions: Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA;   Childhood Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Myeloid Neoplasm
Interventions: Drug: Arsenic Trioxide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Idarubicin;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone Hydrochloride;   Other: Questionnaire Administration;   Drug: Tretinoin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.